UDCA reduces risk of primary biliary cirrhosis recurrence following liver transplant
01 Dec 2015
Ursodeoxycholic acid (UDCA) reduces the risk of primary biliary cirrhosis (PBC) recurrence following liver transplant as presented in a retrospective study. Patients with UDCA prophylaxis achieved lower PBC recurrence rates in 5, 10 and 15 years compared with non-UDCA users (11, 21, 40 percent vs 32, 53, 70 percent, respectively).
Related MIMS Drugs